Theranica Overview
Theranica develops advanced, clinically proven, safe and affordable digital therapeutics, addressing some of the world’s most prevalent neurological pain diseases. Theranica is the developer of Nerivio, a fully integrated, self-contained family of therapeutic patches. The patches and other types of wearables in the companys pipeline are controlled by smartphone applications to easily adapt therapy treatments to everyday life. Nerivio Migra is a migraine-relief patch that provides migraine treatment through neuromodulation. Instead of placing electrodes on their head, patients can attach Theranicas clinically tested, wearable patch to their arm and launch a personalized pain-relief program. Theranica combines electrical neurostimulation and neuromuscular stimulation technologies with modern wireless communication and smartphone applications. The company uses these advanced technologies to design and deliver effective products for treating a variety of severe and common medical problems. In May 2019, Theranica won FDA De Novo clearance for its Nerivio Migra device. In June 2019, the company announced the establishment of a wholly owned subsidiary company, Theranica USA, headquartered in Montclair, New Jersey.
Cumulative Funding Raised Over Time ($)
$1.0MAug 2016
$46.0MAug 2022
$52.0MJun 2017
$87.0MMar 2019
$88.1MSep 2021
Latest News
Nerivio announces new study indicating meaningful impact of Nerivio from as early as two weeks
growth-positive
תרניקה: הוכחנו יעילות מובהקת בטיפול במיגרנות - Techtime - חדשות אלקטרוניקה והייטק
Theranica, an Israeli company, has developed a bio-electronic device called Nervio that significantly reduces migraine pain through electrical signals. A comprehensive study involving 248 migraine sufferers in the US showed a reduction of 4.7 migraine days per month for chronic sufferers and a reduction of 3.2 days for episodic sufferers. The device has no side effects and is expected to help the company in marketing the device in the US and creating awareness among doctors and patients. In August, Theranica raised $45 million to expand its marketing and sales operations in the US and to promote interaction with the medical establishment.
InvestmentCustomers
growth-positive
Theranica Secures $45 Million Series C Funding Round
Theranica, a prescribed digital therapeutics company, has closed its Series C funding round with a first closing of $45 million. The funding, led by New Rhein Healthcare Investors, will be used to expand the companys commercial activity in the U.S. Theranica develops advanced neuromodulation devices for migraine and other pain conditions. Its flagship product, Nerivio, is an FDA-cleared, prescribed, smartphone-controlled, drug-free wearable device for the treatment of migraine. The device utilizes remote electrical neuromodulation to trigger an endogenous analgesic mechanism. The company aims to bring effective, drug-free therapeutic options to millions of people with migraine and other chronic pain diseases.
Investment
growth-positive
Costco Wholesale Corporation Adds Nerivio® to Its Member Prescription Program
Theranicas FDA-cleared flagship product Nerivio is now offered to Costco Members Prescription Program (CMPP) members at an exclusive rate, making it the first time a migraine treatment device is offered to CMPP members. Nerivio is a smartphone-controlled, drug-free wearable device for the treatment of migraine. The collaboration with Costco allows under-insured and non-insured people to have affordable access to Nerivio. The CMPP website helps members receive a Nerivio prescription online. This collaboration is a major step in bringing effective drug-free migraine relief to millions of people.
CustomersPartners
growth-positive
https://www.jpost.com/health-and-wellness/mind-and-spirit/us-study-shows-israeli-device-effective-against-chronic-migraines-683010
Theranicas Nerivio device, an electronic wearable medical device developed in Israel, has been shown to significantly reduce pain and symptoms in patients with chronic migraines. A study demonstrated that remote electronic neuromodulation (REN) is an effective and safe treatment for chronic migraine patients. The device, approved by the US FDA, sends non-painful electrical waveforms to nerve fibers in the upper arm, triggering conditioned pain modulation (CPM) in the central neural system. The study found that nearly 60% of patients experienced pain relief within two hours of treatment, with sustained relief for at least 24 hours. The device has a high safety profile. Theranica recently announced a partnership with MC-Rx, a pharmacy benefit manager, for reimbursement of the Nerivio device.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $88.1M |
| Last funding | $45M |
| Stage | C |
| Rounds | 5 |
| Investors | 10 |
Team Members
5
Employees: 51-200
Web & Social Links
| Website | theranica.com |
| Careers | Careers page |
| App Store | App Store |
| Google Play | Google Play |
Locations
Ha-Omanut St 4, Netanya, Israel
151 Forest St, Montclair, NJ 07042, USA
Photos & Videos
2 item(s)
Theranica Business
Business models
B2C, B2B2C
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesDigital HealthcareDigital TherapeuticsTarget Customer
ConsumersDemographics & FamilyWomenTeenagers & Young AdultsHealthcare & Life SciencesHealthcarePatientsCore Technology
Semiconductors & ElectronicsWearablesPlatforms & InterfacesMobileTags (17)
mhealthdigital-healthcarewearablenon-invasivemedical-devicesmobile-platformpain-reliefpersonalizationneurologypatientsneuro-stimulationmobile-applicationswellnesswomendigital-therapeuticschronic-patientswomen-healthGeographic Markets
EuropeChinaIndiaUnited StatesTheranica Financials
$88.1M
Total funding
Undisclosed
Capital raised
$45M
Last funding
C
Funding stage
5
Total rounds
10
Investors
Cumulative Funding Raised Over Time ($)
$1.0MAug 2016
$46.0MAug 2022
$52.0MJun 2017
$87.0MMar 2019
$88.1MSep 2021
Private Equity Funding
C Round
Aug 2022
$45M
New Rhein Healthcare Investors (Lead)
,
LionBird, Takoa, aMoon Fund, Corundum Open Innovation, Lightspeed Venture Partners
Convertible Debt
Sep 2021
$1.1M
Infinity Medical
B Round
Mar 2019
$35M
Omron Ventures, Corundum Open Innovation, LionBird, Takoa, Lightspeed Venture Partners, aMoon Fund
A Round
Jun 2017
$6M
LionBird, Corundum Open Innovation, Lightspeed Venture Partners
Seed
Aug 2016
$1M
Undisclosed Investor(s), Dr. Shimon Eckhouse
Theranica Lifecycle
Cumulative Funding Raised Over Time
$1.0MAug 2016
$46.0MAug 2022
$52.0MJun 2017
$87.0MMar 2019
$88.1MSep 2021
All Events
C Round
Aug 2022
$45M
New Rhein Healthcare Investors (Lead)
,
LionBird, Takoa, aMoon Fund, Corundum Open Innovation, Lightspeed Venture Partners
Convertible Debt
Sep 2021
$1.1M
Infinity Medical
B Round
Mar 2019
$35M
Omron Ventures, Corundum Open Innovation, LionBird, Takoa, Lightspeed Venture Partners, aMoon Fund
A Round
Jun 2017
$6M
LionBird, Corundum Open Innovation, Lightspeed Venture Partners
Seed
Aug 2016
$1M
Undisclosed Investor(s), Dr. Shimon Eckhouse
Theranica News
34 articlesNerivio announces new study indicating meaningful impact of Nerivio from as early as two weeks
growth-positive
תרניקה: הוכחנו יעילות מובהקת בטיפול במיגרנות - Techtime - חדשות אלקטרוניקה והייטק
Theranica, an Israeli company, has developed a bio-electronic device called Nervio that significantly reduces migraine pain through electrical signals. A comprehensive study involving 248 migraine sufferers in the US showed a reduction of 4.7 migraine days per month for chronic sufferers and a reduction of 3.2 days for episodic sufferers. The device has no side effects and is expected to help the company in marketing the device in the US and creating awareness among doctors and patients. In August, Theranica raised $45 million to expand its marketing and sales operations in the US and to promote interaction with the medical establishment.
InvestmentCustomers
growth-positive
Theranica Secures $45 Million Series C Funding Round
Theranica, a prescribed digital therapeutics company, has closed its Series C funding round with a first closing of $45 million. The funding, led by New Rhein Healthcare Investors, will be used to expand the companys commercial activity in the U.S. Theranica develops advanced neuromodulation devices for migraine and other pain conditions. Its flagship product, Nerivio, is an FDA-cleared, prescribed, smartphone-controlled, drug-free wearable device for the treatment of migraine. The device utilizes remote electrical neuromodulation to trigger an endogenous analgesic mechanism. The company aims to bring effective, drug-free therapeutic options to millions of people with migraine and other chronic pain diseases.
Investment
growth-positive
Costco Wholesale Corporation Adds Nerivio® to Its Member Prescription Program
Theranicas FDA-cleared flagship product Nerivio is now offered to Costco Members Prescription Program (CMPP) members at an exclusive rate, making it the first time a migraine treatment device is offered to CMPP members. Nerivio is a smartphone-controlled, drug-free wearable device for the treatment of migraine. The collaboration with Costco allows under-insured and non-insured people to have affordable access to Nerivio. The CMPP website helps members receive a Nerivio prescription online. This collaboration is a major step in bringing effective drug-free migraine relief to millions of people.
CustomersPartners
growth-positive
https://www.jpost.com/health-and-wellness/mind-and-spirit/us-study-shows-israeli-device-effective-against-chronic-migraines-683010
Theranicas Nerivio device, an electronic wearable medical device developed in Israel, has been shown to significantly reduce pain and symptoms in patients with chronic migraines. A study demonstrated that remote electronic neuromodulation (REN) is an effective and safe treatment for chronic migraine patients. The device, approved by the US FDA, sends non-painful electrical waveforms to nerve fibers in the upper arm, triggering conditioned pain modulation (CPM) in the central neural system. The study found that nearly 60% of patients experienced pain relief within two hours of treatment, with sustained relief for at least 24 hours. The device has a high safety profile. Theranica recently announced a partnership with MC-Rx, a pharmacy benefit manager, for reimbursement of the Nerivio device.
Customers
growth-positive
אינפיניטי השקיעה 3.5 מיליון שקל בתרניקה - Techtime - חדשות אלקטרוניקה והייטק
Theranica, an Israeli medical device company, has signed a partnership agreement with Infinity Medical for the distribution and production of its pain management system, Nerivio, in China. Infinity Medical has invested 3.5 million shekels in Theranica to support the companys manufacturing and distribution in China. The partnership aims to promote Israeli medical companies in the Chinese market. Theranicas Nerivio system uses electrical stimulation to treat chronic pain and received FDA approval in early 2021. The companys non-invasive and user-friendly system has gained recognition in the market. Theranica has raised a total of $41 million in funding, with the largest funding round completed in March 2019 led by Aquarius.
PartnersInvestment
growth-positive
Theranica Announces the Establishment of a Unique Level II HCPCS Code by the Centers for Medicare and Medicaid Services (CMS)
Theranica, a digital therapeutics company, announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a new HCPCS Level II code for its product Nerivio. The code will become effective on October 1, 2021. Nerivio is a drug-free remote electrical neuromodulation device for the acute treatment of migraine. The creation of this new code acknowledges the unique aspects of Theranicas technology and helps distinguish its device from other modalities. This milestone is a significant step towards gaining favorable coverage for patients with migraine who are prescribed this therapy.
Customers
growth-positive
Peer-Reviewed Study Suggests Nerivio® Effective for Treatment of Acute Menstrual Migraine Headache
Theranica, a digital therapeutics company, announced the efficacy of Nerivio in treating menstrual migraine. A new peer-reviewed study demonstrated that Nerivio was at least moderately effective in treating menstrual migraine and associated symptoms. The treatment was found to be tolerable with mild and short-term side effects. The study also observed some improvement in menstrual cramping and pelvic pain. Menstrual migraine affects a significant percentage of female migraineurs, and the positive study results solidify the role of Remote Electrical Neuromodulation in the therapy toolkit for women with migraine. Theranicas flagship product, Nerivio, is the first FDA-cleared smartphone-controlled prescription wearable device for acute treatment of migraine.
Customers
growth-positive
Migraine device wins 2021 MedTech Breakthrough Award
Theranicas Nerivio therapeutic wearable for treating migraine pain won the “Best New Technology Solution for Pain Management” award in the MedTech Breakthrough Awards program. The FDA-approved device uses remote electrical neuromodulation to treat migraine symptoms and is personalized through the Nerivio app. Since its launch, Nerivio has treated over 100,000 migraines in over 14,000 patients. The award recognizes Theranicas innovative approach to migraine treatment and its positive impact on patients.
Customers
growth-positive
Nerivio® Drug-free Wearable Surpasses 100,000 Migraine Treatments in the US
Theranica has experienced consistent growth in the usage of its prescribed digital therapeutic, Nerivio, with over 100,000 treatments in the USA. The company has also seen a 33% growth in monthly active users. A recent study published in Headache showed that Nerivio provided pain relief and pain freedom for migraine patients. Theranicas Nerivio is eligible for insurance coverage, and the out-of-pocket patient payment can be as low as zero dollars per unit. Theranica is focused on developing effective, safe, and affordable electroceuticals for pain conditions.
CustomersInvestment
growth-positive
Theranica's migraine DTx receives FDA clearance for adolescent use
Theranica, an Israeli prescription digital therapeutics developer, has received FDA clearance for its Nerivio device for the acute treatment of migraine. The device is a wireless, noninvasive remote electrical-stimulation wearable that activates the brains pain modulation mechanism. The clearance expands the devices indication for migraine treatment in adolescents. Clinical trials showed that 71% of adolescent participants experienced pain relief after two hours, and 35% experienced complete freedom from pain. The device provides a drug-free option for teens who may have contraindications or prefer not to take pills.
Customers
growth-positive
Largescale Real-World Migraine Study Solidifies Efficacy And Safety of Theranica's Nerivio® Device
Theranica, a prescribed digital therapeutics company, announced the publication of a real-world post-marketing surveillance study that demonstrates the safety and efficacy of its Nerivio therapeutic wearable device for migraine treatment. The study showed positive results for migraine patients, with a significant percentage experiencing pain relief and improvement in functioning. The device, which is controlled through a mobile app, allows patients to easily share their migraine data with doctors. The study also highlighted the added value of digital therapeutics. The company aims to provide drug-free treatment alternatives and help patients reduce their consumption of drugs. Theranicas Nerivio has received FDA clearance for acute treatment of episodic migraine and is currently under review for chronic migraine. The company is dedicated to creating effective, safe, and affordable solutions for pain conditions.
Customers
growth-positive
Nerivio® Smartphone-Controlled Wearable for Acute Treatment of Migraine Granted CE Mark for Use in Europe
Theranica has been granted a CE mark for its Nerivio device for the acute treatment of migraine, allowing it to be marketed in select countries in Europe starting in 2021. This milestone is expected to have a positive impact on the companys growth. The Nerivio device is the first smartphone-controlled wearable device for migraine treatment, providing a non-pharmacological therapy option for migraine patients. The company aims to expand its proprietary technology to offer solutions for other pain conditions. An estimated 41 million Europeans suffer from migraines, and the CE mark approval will provide them with a new treatment option.
Customers
growth-positive
Theranica Reports Positive Study Results of Nerivio® for Chronic Migraine Patients
Theranica, a digital therapeutics company, announced the results of a new study that demonstrates the effectiveness of incorporating Remote Electrical Neuromodulation (REN) into the usual care of chronic migraine. The study evaluated Theranicas FDA-cleared acute migraine treatment device Nerivio and showed that 73.7% of participants achieved pain relief at 2 hours and 26.3% were pain-free in at least half of their treatments. The study also found that REN provides consistent response rates from treatment to treatment, with no evidence of reduction in therapeutic benefits over time. This study is significant for chronic migraine sufferers who need well-tolerated and effective solutions. Theranicas Nerivio is a prescribed therapeutic wearable that uses REN to activate the bodys native Conditioned Pain Modulation (CPM) mechanism to treat pain and migraine symptoms.
Customers
growth-positive
Theranica Kicks Off Migraine & Headache Awareness Month Rebate Program for Nerivio®, Its FDA-Authorized Migraine Treatment Wearable
Theranica, a prescribed digital therapeutics company, announced a $50 rebate for new Nerivio prescriptions dispensed during June 2020. Nerivio is an FDA-authorized prescription wearable for the acute treatment of migraine. The rebate program aims to make Nerivio more accessible and affordable for patients. The company is seeking insurance coverage and reimbursement to fulfill its vision. Patients can obtain a Nerivio prescription through licensed healthcare providers or telemedicine platforms. Each Nerivio unit with 12 treatments is discounted to $99, and the rebate reduces the cost to just over $4 per treatment. The rebate will be granted to all newly prescribed patients upon the completion of eight treatments. Theranica is a dedicated company in creating effective, safe, and low-side effect electroceuticals for pain conditions.
Customers
growth-positive
Theranica Expands Executive Team Amid Growing US Demand for Its FDA-authorized Migraine Treatment Wearable Device
Theranica USA, a subsidiary of Theranica Bioelectronics, has appointed two senior executives to meet the growing demand for its prescription migraine treatment device, Nerivio. The company has hired Dave Duff as Head of Marketing and Training, and Jennifer Stanton as Head of Market Access. Nerivio is an FDA-authorized wearable device that provides drug-free therapy for acute migraine treatment. Theranica has expanded the availability of Nerivio through telemedicine partnerships and is planning a reimbursement initiative to make the treatment more accessible. The company has already treated over 5,000 patients and provided over 30,000 treatments in a limited launch program. Each Nerivio unit can be used for 12 migraine treatments and can be recycled and refilled with a new device.
Management ChangesPartnersCustomers
growth-positive
Theranica Expands Accessibility of Nerivio™ to U.S. Migraine Patients Via Partnership With Telemedicine Platform, Cove
Theranica Bioelectronics and Cove have announced the expanded availability of Nerivio, a novel FDA-authorized prescribed wearable for acute treatment of migraine, on Coves advanced telemedicine platform. Nerivio uses electrical signals to inhibit pain messages to the brain and is controlled via a smartphone app. Previously, Nerivio could only be accessed in limited geographic areas, but now it is available to migraine sufferers nationwide through Coves platform. Cove offers a range of preventive and acute migraine treatments and connects individuals with physicians for specialized migraine care. The partnership aims to provide quick and affordable relief to migraine patients.
PartnersCustomers
growth-positive
Migraine-Zapping Device Developed By Israeli Biomedical Firm Offers Hope For Sufferers
Israeli biomedical company Theranica Bioelectronics specializes in combining neuromodulation therapy with wireless technology to develop wearable devices for pain mitigation, particularly migraines. Their device, the Nerivio, has received FDA clearance for acute treatment of migraines and has shown high efficacy in clinical trials. Theranica has raised $41 million from investors including aMoon and Lightspeed Venture Partners. The company plans to expand its offerings to other pain conditions after appropriate clinical development. The Nerivio is priced at $99 and is available in select headache and migraine clinics in the US, with availability in Israel expected later this year.
CustomersInvestment
growth-positive
Israeli Firm Theranica, Developer Of Migraine-Zapping Device, Hailed As 2020 'Game-Changer'
Israeli biomedical tech company Theranica, known for its advanced wearable devices, was named one of the game-changing companies in 2020 by CB Insights. Theranicas migraine-zapping wearable device, Nerivio, received FDA approval and was recognized as one of TIME magazines best inventions of 2019. The device provides migraine treatment through neuromodulation therapy and is controlled via app. Theranica raised $35 million in a Series B funding round led by aMoon earlier this year.
Investment
growth-positive
Theranica: Journal of Expert Review of Medical Devices Publishes Profile of Nerivio™
Theranica Bio-Electronics announced that the journal of Expert Review of Medical Devices has published a device profile of its smartphone-controlled migraine wearable device, Nerivio. The article highlights the safety and efficacy of the device, positioning it as a highly effective and affordable alternative to traditional pharmacological therapies. The device uses remote electrical neuromodulation to stimulate peripheral nerves in the upper arm and mitigate pain. Nerivio has undergone two randomized trials demonstrating its efficacy and non-inferiority to traditional care and acute pharmacological treatments. The product received FDA clearance in May 2019 and was recognized by TIME Magazines Best Inventions 2019. Theranica is a bio-medical technology company focused on developing advanced electroceuticals for migraine and other pain disorders.
Customers
growth-positive
Theranica's Nerivio™ Named in TIME's List of 100 Best Inventions of 2019
Theranica Bioelectronics smartphone-controlled prescription migraine wearable device, Nerivio, has been recognized in TIME Magazines annual list of the 100 Best Inventions. The device offers a non-invasive, low side-effect, and drug-free alternative for migraine relief. Theranica aims to make migraine solutions affordable and accessible. Nerivio received FDA approval and is available in select clinics in the US. Theranica is a bio-medical technology company focused on developing advanced electroceuticals for pain disorders.
Partners
growth-positive
Theranica Announces U.S. Recycling Partnership in Commitment to Sustainable Medical Device Production
Theranica Bioelectronics has announced a partnership with California Electronic Asset Recovery, Inc. (CEAR) to recycle its smartphone-controlled prescribed wearable for migraine treatment, Nerivio. The partnership with CEAR will allow consumers to easily send used Nerivio devices for recycling, contributing to the circular economy. Theranica is committed to developing sustainable and environmentally friendly medical devices. Nerivio is the first smartphone-controlled migraine wearable to receive FDA authorization and is already available in over 100 headache clinics in the US. The wearable is made up of recyclable components and can be used for 12 migraine treatments before being replaced. The used devices can be sent to CEAR for recycling.
Partners
growth-positive
Theranica Bioelectronics Hopes to Take Migraine Device Global
Theranica Bioelectronics, a privately-owned company, is planning to take its FDA-approved device, Nerivio Migra, global to treat patients suffering from migraines. The device uses advanced neuromodulation therapy with wireless technology to develop electroceuticals for migraines and other pain disorders. The company plans to pilot launch and market the device in the US with limited availability later this year, and in Europe and Israel next. Theranica received $35 million in Series B funding in May, which will help it continue with its plans to market, sell and develop the product.
InvestmentExpand
growth-positive
New Study Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute Medications
Theranica, a bio-medical technology company, has published a peer-reviewed paper demonstrating the effectiveness of its Nerivio REN device in treating the symptoms of migraine. The study compared the device to usual care in adult migraine patients and found that pain relief was achieved by 66.7% of participants following REN treatment, compared to 52.5% with usual care. Additionally, 50.0% of participants were pain-free at two hours following REN treatment. The study also showed that RENs efficacy is unaffected by the use of migraine preventive medications. The Nerivio device, which has received FDA market authorization, is applied to the upper arm for 45 minutes at the start of a migraine attack, stimulating the nerves and inducing conditioned pain modulation.
Customers
growth-positive
https://www.jpost.com/Opinion/Hillels-Tech-corner-Disrupting-the-migraine-business-594657
Theranica, a biomedical technology company, has received FDA de novo clearance for its wearable device called Nerivio, which provides pain relief for migraines. The device stimulates the internal conditioned pain modulation mechanism to mitigate pain. Theranica recently raised $35 million in Series B funding, bringing the total investment to $41 million. The company has a partnership with Omron Corporation and has launched its subsidiary, Theranica USA. The Nerivio device will be available in limited quantities in the US later this year, with wider distribution in 2020. Theranica plans to develop solutions for other painful disorders and conduct research for a broader audience, including children.
CustomersInvestmentPartnersExpand
growth-positive
Theranica Appoints Senior Executives to Lead its New USA Subsidiary
Theranica Bioelectronics has announced the establishment of its subsidiary company, Theranica USA, and the appointment of senior executives to lead the commercialization of Nerivio, a smartphone-controlled wearable device for acute treatment of migraine. The company was granted FDA De Novo authorization for Nerivio in May 2019. The newly appointed executives will lead the launch of the device in the US market. Migraine affects over 1 billion people globally and 39 million Americans. Nerivio uses electronic pulses to inhibit migraine-associated headache and other symptoms. Theranica USA aims to provide an affordable, non-invasive, drug-free alternative for acute migraine.
Customers
growth-positive
Theranica: New Publication Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute Medications
Theranica, a bio-medical technology company, has published a peer-reviewed paper demonstrating the effectiveness of its Remote Electrical Neuromodulation (REN) device in treating the symptoms of migraine. The study compared the efficacy of Theranicas Nerivio REN device to previous acute care treatments in the same patients. The results showed that REN was as effective as pharmacological treatments in providing pain relief and that its efficacy was unaffected by the use of migraine preventive medications. The FDA has authorized the market release of Theranicas Nerivio device, which is a wearable for the acute treatment of migraine. The company aims to provide safe and effective alternatives for migraine patients who may experience challenges with traditional medications.
Customers
growth-positive
Nerivio Migra Wins FDA De Novo Clearance for Acute Treatment of Migraines
Theranica, an Israeli company, has received FDA De Novo clearance for its Nerivio Migra smartphone-operated electroceutical device for treating migraines. The device, worn around the upper arm, delivers electronic pulses to generate a pain modulation response. It is controlled by a smartphone app and is expected to be available in the US later this year. The company plans to expand the use of its technology for other types of pain. The clearance was based on a study involving 252 patients. Theranica aims to offer the Nerivio Migra at an affordable price.
Customers
growth-positive
OMRON VENTURES Joins Theranica's Series B Funding Round as Strategic Investor
OMRON VENTURES has joined Theranicas $35 million series B funding round. The funding will allow Theranica to mass produce its product, Nerivio Migra®, a remote electrical neuromodulation device for acute treatment of migraine. Theranica combines advanced neuromodulation therapy with modern wireless technology to develop proprietary electroceuticals that address medical conditions and diseases. OMRON VENTURES, the venture capital arm of OMRON Corporation, is committed to supporting Theranicas mission of improving peoples health at home through science and technology.
Investment
growth-positive
Israeli migraine device co Theranica raises $35m
Theranica, an Israeli migraine device treatment company, has closed a $35 million Series B financing round led by aMoon. The funds will be used to mass-produce their remote neuromodulation device, Nerivio Migra, and seek FDA clearance to deliver the device to migraine patients in the US. The company aims to target additional clinical syndromes and improve migraine therapy worldwide. The investment aligns with Theranicas vision and will support the commercialization of their innovative, non-invasive, drug-free solution.
Investment
growth-positive
Brian Grosberg, MD: Nerivio Migra Device for Acute Migraine Treatment
Theranica, a biomedical technology developer, announced positive results for its Nerivio Migra device in a clinical trial for the treatment of migraine. The device demonstrated a 66.7% response rate in pain relief at 2 hours post-treatment, compared to 38.8% in the placebo arm. The studys findings show the potential of the device as a non-invasive treatment option for acute migraine.
Customers
growth-positive
Theranica Announces Results from Pivotal Study of Device for Treating Acute Migraine
Theranica, a biomedical technology company, announces the results of a clinical study for their non-invasive neuromodulation device for the treatment of migraines. The study shows significant benefits and high statistical significance in pain relief and other secondary endpoints. The device has the potential to provide a drug-free acute treatment for migraines. Regulatory submission has been filed in the United States, and Theranica plans to commercialize the device by the end of 2019.
Customers
growth-positive
Theranica Raises $6M to Combat Migraine
Theranica Bio-Electronics has closed its round A financing, led by Lightspeed Venture Partners, with participation from LionBird venture capital firm and Corundum Open Innovation. The company plans to use the funds, totaling about $6M, to complete the regulatory process for its first product, an acute treatment for migraine, and to bring the product to mass production. Theranica develops advanced electroceuticals for migraine and other diseases, combining advanced electronics and wireless communication technologies. The company is currently conducting a clinical study in the US and Israel. The investment will help Theranica address the growing market for effective migraine solutions.
Investment
growth-positive
Theranica Bio-Electronics Closes Seed Financing Round - FinSMEs
Theranica Bio-Electronics, a medical device company, has closed a seed financing round led by angel investors. The company offers a smart patch that delivers neuromodulation therapy for various medical conditions, with the first application being the treatment of migraine headaches. The patch consists of a proprietary smart chip controlled by a smartphone app. The funding will support the development and commercialization of the companys wearable solutions.
Investment
Theranica Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 89 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 14 classification IDs that could be used for matching.
Theranica Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 102/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515419059 |
| Crunchbase | theranica |
| Phone | +972723909762 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-10-18T00:00:00.000Z |
| Created | 2016-09-21T00:00:00.000Z |
| Claimed | Yes |